On March 10, 2021 Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, reported that the latest preclinical research results of the company’s five novel drug candidates have been selected for presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2021, and have already been published in the meeting’s official website (Press release, Ascentage Pharma, MAR 10, 2021, View Source [SID1234576436]). This year’s AACR (Free AACR Whitepaper) annual meeting will be held in a virtual format on April 27-28 and June 22-24.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The AACR (Free AACR Whitepaper) annual meeting is one of the world’s largest and long-standing scientific gatherings in the field of cancer research. Covering some of the most cutting-edge advances in all the areas of oncology research and innovation, the annual event attracts tremendous interest from the global cancer research community.
"It is our great pleasure to have the research results of our drug candidates selected by the AACR (Free AACR Whitepaper) annual meeting several years in a row, and this year, our presentations will focus on results from the translational research of multiple drug candidates that have already entered into clinical development," said Dr. Yifan Zhai, Chief Medical Officer of Ascentage Pharma. "These studies deepened our understanding of our drug candidate’s mechanism of actions, provided supportive evidence to our strategy for combination options and potential disease indications, and have therefore further advanced our clinical development of these therapeutic candidates."
The six abstracts selected for poster presentations at the AACR (Free AACR Whitepaper) Annual Meeting 2021 include:
Title:
BCL-2 inhibitor APG-2575 and homoharringtonine (HHT) synergistically induces apoptosis and inhibits tumor growth in preclinical models of acute myeloid leukemia and myelodysplastic syndromes (AML/MDS)
Abstract/Poster Number: 981
Session Category: Experimental and Molecular Therapeutics
Session Title: Cell Death Pathways and Treatment
Title:
Inhibition of BCL-2 (by APG-2575) and CDK4/6 synergistically induces cell cycle arrest and apoptosis in ER⁺ breast cancer
Abstract/Poster Number: 976
Session Category: Experimental and Molecular Therapeutics
Session Title: Cell Death Pathways and Treatment
Title:
FMS-like tyrosine kinase 3 (FLT3) inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor APG-2575 in preclinical models of FLT3-mutant acute myeloid leukemia (AML)
Abstract/Poster Number: 1096
Session Category: Experimental and Molecular Therapeutics
Session Title: Drug Resistance in Molecular Targeted Therapies
Title:
Therapeutic potential of inhibitor of apoptosis protein (IAP) inhibitor APG-1387 combined with DR5 agonist monoclonal antibody (mAb) CTB-006 in preclinical models of solid tumors
Abstract/Poster Number: 1924
Session Category: Molecular and Cellular Biology / Genetics
Session Title: Apoptosis
Title:
Targeting BCL-xL addiction with APG-1252 (pelcitoclax) to overcome apoptotic blockade in neuroendocrine neoplasm (NEN)
Abstract/Poster Number: 984
Session Category: Experimental and Molecular Therapeutics
Session Title: Cell Death Pathways and Treatment
Title:
Focal adhesion kinase (FAK) inhibitor APG-2449 sensitizes ovarian tumors to chemotherapy via CD44 downregulation
Abstract/Poster Number: 968
Session Category: Experimental and Molecular Therapeutics
Session Title: Biological Therapeutic Agents